Patent Issued for Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device (USPTO 12201721).

A patent has been issued for clotting factor preparations that can be delivered into the tissue of the intestinal tract using a swallowable drug delivery device. This innovation aims to provide an alternative method for delivering clotting factors such as Factor VIII, which are traditionally administered through injections. The technology is designed to address limitations and challenges associated with current forms of hemophilia treatments, including the development of antibodies that can reduce the effectiveness of clotting factors. [Extracted from the article]